The acute effects of a dopamine d3 receptor preferring agonist on motivation for cigarettes in dependent and occasional cigarette smokers

Nicotine and Tobacco Research

Volumn 20, Issue 7, 2018, Pages 800-809

  Lawn, Will ^a   Freeman, Tom P ^a,b   East, Katie ^b   Gaule, Annie ^a   Aston, Elizabeth R ^e   Bloomfield, Michael A P ^a,c   Das, Ravi K ^a   Morgan, Celia J A ^a,d   Curran, H Valerie ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EXETER   (United Kingdom)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR; PLACEBO; PRAMIPEXOLE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRAVING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL TASK; MOTIVATION; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REWARD; SMOKING; SMOKING CESSATION; TASK PERFORMANCE; TOBACCO DEPENDENCE; YOUNG ADULT; ADDICTION; CIGARETTE SMOKING; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; PHYSIOLOGY; PSYCHOLOGY;

ADULT; BEHAVIOR, ADDICTIVE; CIGARETTE SMOKING; CRAVING; CROSS-OVER STUDIES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MOTIVATION; PRAMIPEXOLE; RECEPTORS, DOPAMINE D3; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 85032483160     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntx159     Document Type: Article

References (53)

1. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274-5278
2. Salamone JD, Correa M. Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res. 2002;137(1-2):3-25
3. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28(3):309-369
4. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593-1599
5. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci. 2015;16(5):305-312
6. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557-569
7. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18(3):247-291
8. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12(11):652-669
9. Anselme P. The effect of exposure to drugs on the processing of natural rewards. Neurosci Biobehav Rev. 2009;33(3):314-335
10. Fehr C, Yakushev I, Hohmann N, et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry. 2008;165(4):507-514
11. Leroy C, Karila L, Martinot JL, et al. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict Biol. 2012;17(6):981-990
12. Rose EJ, Ross TJ, Salmeron BJ, et al. Chronic exposure to nicotine is associated with reduced reward-related activity in the striatum but not the midbrain. Biol Psychiatry. 2012;71(3):206-213
13. Jansma JM, van Hell HH, Vanderschuren LJ, et al. THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction. Transl Psychiatry. 2013;3:e234
14. Lawn W, Freeman TP, Hindocha C, et al. The effects of nicotine dependence and acute abstinence on the processing of drug and non-drug rewards. Psychopharmacology (Berl). 2015;232(14):2503-2517
15. Bühler M, Vollstädt-Klein S, Kobiella A, et al. Nicotine dependence is characterized by disordered reward processing in a network driving motivation. Biol Psychiatry. 2010;67(8):745-752
16. Versace F, Lam CY, Engelmann JM, et al. Beyond cue reactivity: blunted brain responses to pleasant stimuli predict long-term smoking abstinence. Addict Biol. 2012;17(6):991-1000
17. Jarvik ME, Caskey NH, Wirshing WC, et al. Bromocriptine reduces cigarette smoking. Addiction. 2000;95(8):1173-1183
18. Murphy MF, Hey K, Johnstone E, et al. Bromocriptine use is associated with decreased smoking rates. Addict Biol. 2002;7(3):325-328
19. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995;290(1):29-36
20. Samuels ER, Hou R, Langley R, Szabadi E, Bradshaw C. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology (Berl). 2006;187(4):498-510
21. Maj J, Rogóz Z, Skuza G, Kolodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol. 1997;324(1):31-37
22. Pizzagalli DA, Evins AE, Schetter EC, et al. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology (Berl). 2008;196(2):221-232
23. Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol. 2005;526(1-3):199-206
24. Freeman TP, Das RK, Kamboj SK, Curran HV. Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward. Soc Cogn Affect Neurosci. 2015;10(1):85-92
25. Freeman TP, Morgan CJ, Brandner B, Almahdi B, Curran HV. Dopaminergic involvement in effort-based but not impulsive reward processing in smokers. Drug Alcohol Depend. 2013;130(1):109-114
26. Zhou X, Nonnemaker J, Sherrill B, Gilsenan AW, Coste F, West R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. Addict Behav. 2009;34(4):365-373
27. Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol. 1997;5(2):137-142
28. Versace F, Engelmann JM, Robinson JD, et al. Prequit fMRI responses to pleasant cues and cigarette-related cues predict smoking cessation outcome. Nicotine Tob Res. 2014;16(6):697-708
29. Leventhal AM, Piper ME, Japuntich SJ, Baker TB, Cook JW. Anhedonia, depressed mood, and smoking cessation outcome. J Consult Clin Psychol. 2014;82(1):122-129
30. MacKillop J, Murphy JG, Ray LA, et al. Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers. Exp Clin Psychopharmacol. 2008;16(1):57-65
31. Aston ER, Metrik J, MacKillop J. Further validation of a marijuana purchase task. Drug Alcohol Depend. 2015;152:32-38
32. Treadway, MT, Buckholtz, JW, Schwartzman AN, et al. Worth the 'EEfRT'? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PloS one. 2009;4(8):e6598
33. Perkins KA, Karelitz JL. Reinforcement enhancing effects of nicotine via smoking. Psychopharmacology (Berl). 2013;228(3):479-486
34. Sweitzer MM, Geier CF, Joel DL et al. Dissociated effects of anticipating smoking versus monetary reward in the caudate as a function of smoking abstinence. Biol Psychiatry. 2014;76(9), 681-688
35. MacKillop J, Brown CL, Stojek MK, Murphy CM, Sweet L, Niaura RS. Behavioral economic analysis of withdrawal-and cue-elicited craving for tobacco: an initial investigation. Nicotine Tob Res. 2012:nts006
36. Hitsman B, MacKillop J, Lingford-Hughes A, et al. Effects of acute tyrosine/ phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology (Berl). 2008;196(4):611-621
37. Heishman SJ, Singleton EG, Pickworth WB. Reliability and validity of a Short Form of the Tobacco Craving Questionnaire. Nicotine Tob Res. 2008;10(4):643-651
38. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl). 2004;177(1-2):195-199
39. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl). 2013;227(1):177-192
40. Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 1997;37(6):520-525
41. Ersche KD, Bullmore ET, Craig KJ, et al. Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch Gen Psychiatry. 2010;67(6):632-644
42. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. Br J Clin Pharmacol. 2007;64(5):591-602
43. Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979;28(14):2161-2165
44. Rouder JN, Speckman PL, Sun D, Morey RD, Iverson G. Bayesian t tests for accepting and rejecting the null hypothesis. Psychon Bull Rev. 2009;16(2):225-237
45. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A. The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse. 2004;54(2):65-71
46. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM. The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse. 2007;61(8):637-645
47. Yang YK, Yao WJ, McEvoy JP, et al. Striatal dopamine D2/D3 receptor availability in male smokers. Psychiatry Res. 2006;146(1):87-90
48. Cousins MS, Stamat HM, de Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl). 2001;157(3):243-253
49. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-691
50. Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl). 2006;184(3-4):628-636
51. Barrett SP. The effects of nicotine, denicotinized tobacco, and nicotinecontaining tobacco on cigarette craving, withdrawal, and self-administration in male and female smokers. Behav Pharmacol. 2010;21(2):144-152
52. Powell J, Dawkins L, Davis RE. Smoking, reward responsiveness, and response inhibition: tests of an incentive motivational model. Biol Psychiatry. 2002;51(2):151-163
53. Kalamboka N, Remington B, Glautier S. Nicotine withdrawal and reward responsivity in a card-sorting task. Psychopharmacology (Berl). 2009;204(1):155-163